Abstract:Abstract Introduction: Pancreatic adenocarcinoma continues to be a highly lethal malignancy (5 yr survival 5%) poorly responsive to all chemo radiation therapies, with only modest improvement with Gemcitabine the current “main line” drug. We have previously demonstrated the C6 Ceramide chemo enhancement of Gemcitabine and other pancreatic chemo agents. The current study explores the mechanism of C6 Ceramide effects on pancreatic chemo resistance pathways – pro-survival and ras-signaling in pancreatic cancer cells. Methods: In vivo: 2-3 month SCID male mice with pancreatic (pan) tumor implants (2 × 106 L3.6 cells) received intraperitoneal (I.P.) injections (3x/wk) of Paclitaxel (Pax) (3.0mg/gm), Gemcitabine (Gem, 10mg/gm) with/without C6 ceramide (10mg/ml) and were observed 6 weeks and tumor response/survival recorded. In vitro: Drug dose Pax 3 ug/ml, Gem 3 ug/ml, C6 Ceramide 10 ug/ml. The MTT anti tumor response was measured in 3 pancreatic lines L3.6, PANC-1, and MIA (Kras mutated). Signaling activation by Western blot utilized antibodies: LY294002, and Wortmannin to block PI3K/AKT pathway, U0126 and PD 98059 to block ERK pathway and Rapamycin to block mTORC1 pathway. Results: Combined therapy with C6 Ceramide induced significant inhibition of exponential tumor growth and prolonged survival by Gem and Pax. Administration of Gem or Pax with C6 Ceramide induced a significant increase in cell death and apoptosis in pancreatic cancer cells (L3.6, PANC-1 and MIA PaCa-2) which were associated with inhibiting perturbations of cell signaling pathways including pro-survival PI3K/Akt/mTOR, and ERK/MAPK, Ras signaling pathways. Pharmacological inhibition with specific signaling pathway inhibitors enhanced cytotoxicity by Gem or Pax, suggesting that survival pathway inhibition might be the key mechanism contributing to C6 Ceramide synergism of Pax or Gem anti-tumor effects. We also showed C6 ceramide potentiation of Cetuximab anti tumor effects on Kras mutant MIA cells thus overcoming (EGFR mAb) resistance by inhibiting pro-survival PI3K/AKT/mTOR pathways and bypassing K-RAS mutant Ras-ERK pathways. Conclusion: C6 Ceramide an apoptosis signal potentiates the anti tumor effects of chemo agents Gemcitabine and Paclitaxel and the biologic EGFR Inhibitor Cetuximab against 3 aggressive pancreatic cancer cell lines by apparent inhibition of the pro-survival PI3K/AKT/mTOR pathways and the Kras mutated ERK/MAPK pathway. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4767. doi:10.1158/1538-7445.AM2011-4767

C6 Ceramide Dramatically Enhances Docetaxel-Induced Growth Inhibition and Apoptosis in Cultured Breast Cancer Cells: a Mechanism Study.

Abstract 221: C6-ceramide Sensitizes the Aggressive L3-6 Pancreatic Cancer Cell Line to Paclitaxel-Mediated Antitumor Effects in Vivo and in Vitro

Synergistic Enhancement Of Cancer Therapy Using A Combination Of Ceramide And Docetaxel

Abstract 4767: C6 Ceramide Sensitizes Multiple Aggressive Pancreatic Cancer Cell Lines to Gemcitabine, Paclitaxel and Cetuximab Mediated Anti Tumor Effects in Vivo and in Vitro

Liposomal C6 Ceramide Activates Protein Phosphatase 1 to Inhibit Melanoma Cells

C6 Ceramide Dramatically Increases Vincristine Sensitivity Both In Vivo And In Vitro, Involving Amp-Activated Protein Kinase-P53 Signaling

C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α -tubulin hyperacetylation both in vitro and in vivo

Ceramide Lipid-Based Nanosuspension for Enhanced Delivery of Docetaxel with Synergistic Antitumor Efficiency.

Enhancement of Docetaxel-Induced Cytotoxicity by Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways in Squamous Cell Carcinoma of the Head and Neck

Paclitaxel Disrupts Polarized Entry of Membrane-Permeable C6 Ceramide into Ovarian Cancer Cells Resulting in Synchronous Induction of Cell Death

Paclitaxel And Ceramide Synergistically Induce Cell Death With Transient Activation Of Egfr And Erk Pathway In Pancreatic Cancer Cells

AMP-activated Protein Kinase (Ampk)/ulk1-Dependent Autophagic Pathway Contributes to C6 Ceramide-Induced Cytotoxic Effects in Cultured Colorectal Cancer HT-29 Cells

Enhancing the Chemosensitivity of MKN-45 Gastric Cancer Cells to Docetaxel via B7H6 Suppression: A Novel Therapeutic Strategy

Epidermal Growth Factor Receptor Blocker C225 Increases Chemosensitivity and Radiosensitivity of Docetaxel Resistant Human Lung Adenocarcinoma Cell Line SPC-A-1/docetaxel

Effects of the Combination of RAD001 and Docetaxel on Breast Cancer Stem Cells

Antitumor and radiosensitizing effect of docetaxel on human hepatocellular carcinoma and its mechanisim in vivo

C-6-Ceramide Nanoliposome Suppresses Tumor Metastasis By Eliciting Pi3k And Pkc Zeta Tumor-Suppressive Activities And Regulating Integrin Affinity Modulation

Π electron-stabilized polymeric micelles potentiate docetaxel therapy in advanced-stage gastrointestinal cancer

Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference

Co-Delivery of Docetaxel and Curcumin Functionalized Mixed Micelles for the Treatment of Drug-Resistant Breast Cancer by Oral Administration